Artimplant Nine-Month Interim Report 2007 Conference Call on November 9, 11:00 AM (GMT+1).VASTRA FROLUNDA, Sweden -- Regulatory News: CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Hans Rosen and CFO See Chief Financial Officer. Lars-Johan Cederbrant present the nine-month Interim Report 2007 on November 9, 11:00 AM (GMT (Greenwich Mean Time) See UTC. GMT - Universal Time 1 +1). The presentation will be in Swedish. Date: Friday, November 9 Time 11.00 CET CET abbr. Central European Time CET Central European Time CET n abbr (= Central European Time) → hora de Europa central CET abbr (GMT+1) Dial in numbers: Swedish participants: +46 (0)8 505 598 53 UK participants: +44 (0)20 3043 2436 US participants: +1 866 458 40 87 A presentation in PDF format will be available on Artimplant's website www.artimplant.com a couple of minutes before the conference call starts. Please note that Artimplant's nine-month interim report 2007 will be distributed with a press release on November 9 2007, 08:45 Central European Time Central European Time Noun the standard time adopted by Western European countries one hour ahead of Greenwich Mean Time, corresponding to British Summer Time Abbrev: (CET) (GMT+1). About Artimplant Artimplant is a biomaterials company focused on solutions to problems in orthopedic and oral surgery. We restore health through the development, production, and marketing of degradable implants that regenerate body functions and improve quality of life. Our products, made from Artelon[R], meet unmet clinical needs and are marketed in a growing number of therapy areas. Artimplant produces implants for treatment of osteoarthritis in hands and feet, for shoulder and other soft tissue injuries as well as oral applications. Artimplant is a public company listed on the OMX Nordic Exchange Stockholm in the Small Cap segment and in the healthcare sector. Forward-looking statements This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence ob·so·les·cent adj. 1. Being in the process of passing out of use or usefulness; becoming obsolete. 2. Biology Gradually disappearing; imperfectly or only slightly developed. ; general economic conditions; and other risks detailed from time to time in the Company's filings. This information was brought to you by Cision http://newsroom.cision.com |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion